Question explored with the scientific record
Can drug Spironolactone affect GFR?
Spironolactone can lower measured GFR, especially in the short term, but the real risk is hyperkalemia, not a permanent drop in kidney function.
The evidence shows a consistent pattern. In a randomized trial of cardiac surgery patients, spironolactone actually increased the risk of acute kidney injury compared to placebo: 43% versus 29% [2]. That is a striking signal. A Japanese pharmacovigilance database also flagged spironolactone as having a strong association with AKI reports, with a reporting odds ratio of 7.36 [3]. These are not subtle findings.
But the picture is more complicated in chronic kidney disease. Several studies show that spironolactone reduces proteinuria, a marker of kidney damage, while causing a modest early dip in eGFR [5, 6, 9]. In the CRIB-II trial, adding spironolactone to an ACE inhibitor or ARB caused an average eGFR drop of about 3% during the first four weeks, but by week 40 the difference from placebo was no longer statistically significant [9]. The trade-off is real: you get less protein leaking into the urine, but you pay for it with a temporary drop in filtration rate and a rise in potassium.
The most dangerous effect is hyperkalemia. In the PRIORITY trial, 13% of spironolactone users hit high potassium levels versus 4% on placebo [4]. A 2025 target-trial emulation comparing spironolactone to the newer drug finerenone found that 26.4% of spironolactone users had potassium over 5.5 mmol/L, and 10.2% over 6.0 mmol/L [7]. That is a serious safety concern, especially for anyone with baseline kidney impairment or taking other drugs that raise potassium.
| Outcome | Spironolactone | Comparator | Source |
|---|---|---|---|
| AKI after cardiac surgery | 43% | 29% (placebo) | [2] |
| Hyperkalemia (≥5.5 mmol/L) in CKD with diabetes | 26.4% | 17.2% (finerenone) | [7] |
| eGFR change at 4 weeks (CKD) | −3% (about −1.6 mL/min) | −0% (placebo) | [9] |
| Proteinuria reduction (CKD, 8 weeks) | −50% from baseline | Not applicable | [5, 6] |
My call: spironolactone can lower measured GFR, especially in the first weeks, and carries a real risk of hyperkalemia that requires monitoring. The benefit is reduced proteinuria. Whether it is worth it depends on your baseline kidney function, potassium levels, and what other drugs you take. Confidence: moderate.
Sources examined 12
-
Mechanisms of Impaired Potassium Handling With Dual Renin-Angiotensin-Aldosterone Blockade in Chronic Kidney Disease
In a randomized crossover study in adults with chronic kidney disease, dual renin-angiotensin-aldosterone blockade (lisinopril plus spironolactone) modestly reduced renal potassium excretion but markedly increased serum potassium, with acute potassium-handling changes predicting…
DOI: 10.1161/hypertensionaha.108.125252 -
The Effect of Spironolactone on Acute Kidney Injury After Cardiac Surgery: A Randomized, Placebo-Controlled Trial
This randomized, placebo-controlled trial investigated the effect of spironolactone on the incidence of acute kidney injury (AKI) in cardiac surgery patients, finding that spironolactone did not provide protective benefits and may even increase the risk of AKI.
DOI: 10.1053/j.ajkd.2016.06.013 -
Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach
A nationwide pharmacovigilance analysis of the Japanese Adverse Drug Event Report (JADER) database identifies drugs most frequently associated with acute kidney injury (AKI) using reporting odds ratios, characterizing patient features, timing, outcomes, and top AKI signals to in…
DOI: 10.1111/jcpt.12748 -
Mineralocorticoid receptor antagonists in patients with chronic kidney disease
A comprehensive narrative review of mineralocorticoid receptor antagonists (MRAs) in chronic kidney disease, outlining their cardiovascular and renal effects, safety concerns (notably hyperkalemia), evidence from trials and registries, and the potential of newer non-steroidal MR…
DOI: 10.1016/j.pharmthera.2020.107701 -
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
This study investigates the long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease, demonstrating significant reductions in proteinuria and a slower decline in estimated glomerular filtration rate compared to conventional t…
DOI: 10.1038/sj.ki.5001854 -
Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
This uncontrolled pilot study evaluates the short-term effects of spironolactone on proteinuria in 42 patients with chronic kidney disease (CKD) already treated with ACE inhibitors and/or ARBs, finding significant reductions in proteinuria and increased serum potassium levels.
DOI: 10.1053/j.ajkd.2005.03.007 -
Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation
Real-world target-trial emulation using TriNetX data shows finerenone reduces all-cause mortality, major adverse cardiovascular events (MACE) and major adverse kidney events (MAKE) and lowers hyperkalemia risk versus spironolactone in adults with chronic kidney disease and type …
DOI: 10.1038/s41467-025-64640-3 -
Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
This article describes the rationale, design, and methodology of ARTS, a multicenter, randomized, double-blind study of BAY 94-8862 (a non-steroidal mineralocorticoid receptor antagonist) in patients with chronic heart failure and mild-to-moderate chronic kidney disease, outlini…
DOI: 10.1093/eurjhf/hfs061 -
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease
This randomized study (CRIB-II) assesses the safety and tolerability of adding low-dose spironolactone to ACE inhibitor/ARB therapy in non-diabetic patients with early-stage CKD, showing low rates of serious hyperkalemia or renal deterioration with intensive monitoring, though m…
DOI: 10.1111/j.1365-2125.2011.04102.x -
OP52 Parathyroid hormone and 25(OH) vitamin D levels in Cameroonian patients with chronic kidney disease: a comparison of diabetic and non-diabetic patients
A collection of African clinical studies focusing on diabetes-related complications and management, including resistant hypertension treated with low-dose spironolactone, CKD-related mineral metabolism differences between diabetics and non-diabetics, ambulatory insulin therapy o…
DOI: 10.1016/S0168-8227(14)70075-0 -
Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease
A commentary summarizing the emerging role of mineralocorticoid receptor antagonists (e.g., spironolactone and finerenone) in chronic kidney disease and dialysis, highlighting trial evidence, potential cardiovascular benefits, safety concerns, and the need for large, definitive …
DOI: 10.1016/S2213-8587(14)70216-5 -
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
This is a comprehensive narrative review arguing that mineralocorticoid receptor (MR) antagonism—including newer non-steroidal agents like finerenone—can reduce cardiovascular risk in chronic kidney disease (CKD) and end-stage renal disease (ESRD) by blocking aldosterone/MR-driv…
DOI: 10.1016/s2213-8587(15)00289-2